NYSE:AMPE Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis $0.0027 -0.13 (-97.93%) As of 06/11/2025 01:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Ampio Pharmaceuticals Stock (NYSE:AMPE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ampio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0027▼$0.002750-Day Range$0.00▼$0.1352-Week Range$0.00▼$0.45Volume140 shsAverage Volume459 shsMarket Capitalization$3.06 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Read More… Ampio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreAMPE MarketRank™: Ampio Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Ampio Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Ampio Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ampio Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmpio Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Ampio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmpio Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmpio Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmpio Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of Ampio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmpio Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media1.1 / 5News SentimentN/A Search Interest2 people have searched for AMPE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Ampio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ampio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Ampio Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 5.73% of the stock of Ampio Pharmaceuticals is held by institutions.Read more about Ampio Pharmaceuticals' insider trading history. Receive AMPE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPE Stock News HeadlinesAmpio Announces Notice of Proposed Settlement of Stockholder Derivative Actions and Settlement HearingJanuary 30, 2025 | markets.businessinsider.comAmpio Pharmaceuticals (OTC:AMPE) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.com2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-year career, uses it to call crashes of 2018 and 2022 – now predicts exact day next crash starts.June 12, 2025 | Chaikin Analytics (Ad)Ampio Pharmaceuticals, Inc. (AMPE)May 17, 2024 | finance.yahoo.comAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationApril 3, 2024 | finance.yahoo.comAmpio Pharmaceuticals Received Audit Opinion with Going Concern ExplanationApril 3, 2024 | prnewswire.comAMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023March 27, 2024 | investorplace.comAmpio Pharmaceuticals IncMarch 26, 2024 | money.usnews.comSee More Headlines AMPE Stock Analysis - Frequently Asked Questions How have AMPE shares performed this year? Ampio Pharmaceuticals' stock was trading at $0.0026 on January 1st, 2025. Since then, AMPE stock has increased by 3.8% and is now trading at $0.0027. View the best growth stocks for 2025 here. How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals, Inc. (NYSE:AMPE) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). When did Ampio Pharmaceuticals' stock split? Ampio Pharmaceuticals's stock reverse split on Tuesday, September 12th 2023. The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ampio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ampio Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Trevena (TRVN), GE Aerospace (GE) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/10/2021Today6/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:AMPE CIK1411906 Webampiopharma.com Phone720-437-6500Fax720-437-6501Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.00Miscellaneous Outstanding Shares1,135,000Free Float1,098,000Market Cap$3.06 thousand OptionableNo Data Beta4.92 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSE:AMPE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-ye...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ampio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.